- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07450144
A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Steatotic Liver Disease
A Large Language Model-based Chatbot for Alcohol Reduction Counseling in SLD Patients: A Pilot Randomized Controlled Trial
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with Steatotic Liver Disease. Specific objectives include:
- To assess how many SLD patients accept the invitation to participate in the trial
- To assess the retention rate of the participants through 3 and 6 months after treatment initiation
- To assess the acceptability of the LLM-based chatbot in terms of participants' compliance and usability rating
- To estimate the intervention effect on alcohol reduction
- To explore the participants' perception and experiences in the chatbot
- To assess the feasibility of implementing Phosphatidylethanol (PEth) testing at the 3-month follow-up
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Hong Kong, Hong Kong
- Recrutamento
- Hong Kong Queen Mary Hospital
-
Contato:
- Man Ping Wang, Prof
- Número de telefone: +85239176636
- E-mail: mpwang@hku.hk
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
1. Hong Kong residents aged 18 years or above 2. Diagnosed of SLD:
-
Evidence of hepatic steatosis (fat accumulation in the liver) confirmed by imaging techniques such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), or liver biopsy
-
Presence of metabolic dysfunction, indicated by at least one of the following:
-
Overweight or obesity (body mass index [BMI] ≥25 kg/m²),
-
Type 2 diabetes mellitus, ③Dyslipidemia (elevated triglycerides [≥150 mg/dL] or low high-density lipoprotein [HDL] cholesterol [<40 mg/dL for men, <50 mg/dL for women]), ④Hypertension (blood pressure ≥130/85 mmHg or use of antihypertensive medication).
- Metabolic syndrome as defined by established criteria (e.g., International Diabetes Federation [IDF], Adult Treatment Panel III [ATP III]) 3. AUDIT-C score of ≥ 3 (women) or ≥ 4 (men) 4. Intention to reduce/quit alcohol 5. Able to read and communicate in Chinese 6. Own a smartphone with internet access
-
-
Exclusion Criteria:
- Diagnosed with mental disease or cognitive impairments, or
- Participating in other ongoing clinic trials
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: LLM-based chatbot
LLM-based chatbot + Alcohol Brief Intervention |
Over the three months following randomisation, an LLM-based chatbot will interact with each participant individually to deliver four personalized sessions of alcohol reduction information and advice, and participants will also be allowed to contact the chatbot at any time. Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet |
|
Comparador Ativo: Telephone counseling
Telephone counseling + Alcohol Brief Intervention |
Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet Over the three months following randomisation, a trained counsellor will conduct four individual daytime telephone sessions with each participant to provide personalised information and advice on reducing alcohol consumption. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Retention rate
Prazo: 6 months after randomisation
|
Number of participants completed the follow-up divided by the number of participants |
6 months after randomisation
|
|
Weekly alcohol consumption
Prazo: 3 months after randomisation
|
Assessed by questions 1 and 2 of AUDIT-C |
3 months after randomisation
|
|
Recruitment rate
Prazo: Through recruitment completion, about 12 months
|
Number of participants divided by the number of eligible subjects |
Through recruitment completion, about 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Weekly alcohol consumption
Prazo: 6 months after randomisation
|
Assessed by questions 1 and 2 of AUDIT-C |
6 months after randomisation
|
|
AUDIT score and level
Prazo: 3 months after randomisation
|
Assessed by the Alcohol Use Disorders Identification Test |
3 months after randomisation
|
|
AUDIT score and level
Prazo: 6 months after randomisation
|
Assessed by the Alcohol Use Disorders Identification Test |
6 months after randomisation
|
|
Eligibility rate
Prazo: Through recruitment completion, about 12 months
|
Number of eligible patients divided by the number of patients screened |
Through recruitment completion, about 12 months
|
|
Frequency of binge drinking in the past 30 days
Prazo: 3 months after randomisation
|
Self-reported |
3 months after randomisation
|
|
Frequency of binge drinking in the past 30 days
Prazo: 6 months after randomisation
|
Self-reported |
6 months after randomisation
|
|
Frequency of heavy drinking in the past 30 days
Prazo: 3 months after randomisation
|
Self-reported |
3 months after randomisation
|
|
Frequency of heavy drinking in the past 30 days
Prazo: 6 months after randomisation
|
Self-reported |
6 months after randomisation
|
|
Planned drinking in the coming 30 days
Prazo: 3 months after randomisation
|
Self-reported |
3 months after randomisation
|
|
Planned drinking in the coming 30 days
Prazo: 6 months after randomisation
|
Self-reported |
6 months after randomisation
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SLD
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .